Additional Study Information: If you want to be a plasma donor please go to (https://recruit.cumc.columbia.edu/clinical_trial/1929). The purpose of this research study is to find out whether antibodies collected from the blood of people, who have been infected with the virus SARS-CoV-2 and recovered from COVID-19, can be used to reduce the risk of severe disease or death in people with COVID-19. This research treatment is also known as convalescent plasma. If you choose to take part in this research study, designed by Dr. Max O'Donnell and Dr. W. Ian Lipkin, and your medical tests show that you are eligible, you will receive one dose of convalescent plasma through an infusion (via IV drip) along with standard treatment or standard treatment with infusion of control plasma. Two patients will receive convalescent plasma treatment for every one patient who receives the control plasma. The selection process is known as randomization. Randomization is like a coin toss; however, chances are twice as high that you will receive the convalescent plasma than the normal plasma. During this study we will ask you questions and collect information about your health, collect blood, conduct physical exams, perform a pregnancy test if you are a woman of child-bearing potential and perform mouth and throat swabs. We will also monitor the progression of your disease.